If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Even with all the precautions taken by medical professionals, infection reportedly occurs in up to 13.9% of patients after stabilization of an open fracture, and in about 0.5-2% of patients who receive joint prostheses. To reduce these numbers, the surfaces of the devices used in these procedures have been altered in hopes of preventing the growth of the bacteria that leads to these infections. This has been achieved by coating titanium devices with an antiseptic combination of chlorhexidine and chloroxylenol. This antiseptic combination successfully prevents the growth of the five main organisms that cause medical-related infections, which include Staphylococcus epidermidis, Methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli and Candida albicans. Peptide-based gel coating with intrinsic antibacterial activity against Methicillin-resistant Staphylococcus aureus, was also shown to inhibit colonization of titanium implants in mice.
Radiation Source Use and Replacement: Abbreviated Version. National Academies Press. ISBN 978-0-309-11014-3. O'Neil, Marydale J.; Heckelman, Patricia E.; Roman, Cherie B., eds. (2006). The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (14th ed.). Merck Research Laboratories, Merck & Co. ISBN 978-0-911910-00-1. Osborne-Lee, I. W.; Alexander, C. W. (1995). "Californium-252: A Remarkable Versatile Radioisotope". Oak Ridge Technical Report ORNL/TM-12706. doi:10.2172/205871. OSTI 205871. Ruiz-Lapuente, P.; Canal, R.; Isern, J. (1996). Thermonuclear Supernovae. Springer Science+Business Media. ISBN 978-0-7923-4359-2. Seaborg, Glenn T.; Loveland, Walter D. (1990). The Elements Beyond Uranium. John Wiley & Sons, Inc. ISBN 978-0-471-89062-1. Seaborg, Glenn T. (1994). Modern alchemy: selected papers of Glenn T. Seaborg. World Scientific. ISBN 978-981-02-1440-1. Seaborg, Glenn T. (1996). Adloff, J. P. (ed.). One Hundred Years after the Discovery of Radioactivity. Oldenbourg Wissenschaftsverlag. ISBN 978-3-486-64252-0. Seaborg, Glenn T. (2004). "Californium". In Geller, Elizabeth (ed.). Concise Encyclopedia of Chemistry. McGraw-Hill. p. 94. ISBN 978-0-07-143953-4. Szwacki, Nevill Gonzalez; Szwacka, Teresa (2010). Basic Elements of Crystallography. Pan Stanford. ISBN 978-981-4241-59-5. Walker, Perrin; Tarn, William H., eds. (1991). Handbook of Metal Etchants. CRC Press. ISBN 978-0-8493-3623-2. Weeks, Mary Elvira; Leichester, Henry M. (1968). "21: Modern Alchemy". Discovery of the Elements. Journal of Chemical Education. pp. 848–850. ISBN 978-0-7661-3872-8.
=== Later work === In 1965, Zuckerkandl moved back to France to direct in Montpellier, the "Centre de Recherche de Biochimie Macromoléculaire" of the Centre National de Recherche Scientifique. In 1971, he became the founding editor of the Journal of Molecular Evolution, and in the late 1970s became President of the Linus Pauling Institute (then in 1992 of its successor, the Institute of Molecular Medical Sciences). His recent work includes criticism of social constructionism and intelligent design.
=== Surgery === Corneal transplant surgery may be difficult due to the peripheral thinning of the cornea, even with large and off-center grafts. Therefore, surgery is usually reserved for people that do not tolerate contact lenses. Several different surgical approaches may be taken, and no one approach is currently established as the standard. Examples of surgical procedures used for PMD include: wedge resection, lamellar crescentic resection, penetrating keratoplasty, lamellar keratoplasty, epikeratoplasty and intracorneal segments. Transplantation of the entire thickness of the cornea (penetrating keratoplasty) may be performed if there is enough normal tissue present. However, if there is not enough normal tissue present, then attaching the graft is difficult. New surgical techniques are in evaluation such as Intrastromal lamellar Keratoplasties and Sclerocorneal Intrastromal Lamellar Keratoplasty (SILK), these techniques allow thickening of the inferior peripheral cornea and steepening of the vertical meridien. Due to the thinning of the cornea, people with PMD are poor candidates for procedures such as LASIK and photorefractive keratectomy.
Cryoneurolysis, also referred to as cryoanalgesia, is a medical procedure that temporarily blocks nerve conduction along peripheral nerve pathways. The procedure, which inserts a small probe to freeze the target nerve, can facilitate complete regeneration of the structure and function of the affected nerve. Cryoneurolysis has been used to treat a variety of painful conditions.
Sources: en.wikipedia.org
The proteins in black mamba venom are of low molecular weight, low viscosity, and the venom's high activity in terms of hyaluronidases, which is also essential in facilitating dispersion of venom toxins throughout tissue (spreading the venom through the body) by catalyzing the hydrolysis of hyaluronan, a constituent of the extracellular matrix (ECM), hyaluronidase lowers the viscosity of hyaluronan, and Dendroaspin natriuretic peptide (DNP), a newly discovered component of mamba venom, is the most potent natriuretic peptide and is unique to the genus Dendroaspis, or mambas. It is a polypeptide analogous to the human atrial natriuretic peptide; it is responsible for causing diuresis through natriuresis and dilating the vessel bloodstream, which results in, among other effects, acceleration of venom distribution in the body of the victim, thereby increasing tissue permeability. These advanced and highly evolved physical and biological features combined with this species' large size, explosive aggression, and quickness make the black mamba a terrifying adversary. Neurological, respiratory, and cardiovascular symptoms rapidly begin to manifest, usually within less than ten minutes. Common symptoms are rapid onset of dizziness, drowsiness, headache, coughing or difficulty breathing, convulsions, and an erratic heartbeat.
Garden officials called the plans "pie-in-the-sky", but on July 24, 2013, the New York City Council voted 47–1 to give the Garden a ten-year operating permit, after which the owners would have to move or seek permission anew. In January 2016, at the same time he announced the development of Moynihan Train Hall, New York governor Andrew Cuomo announced he would solicit proposals for the redevelopment of the station under the Garden as a public-private partnership called the Empire Station Complex. In June 2023, nearing the end of the ten-year permit granted in 2013, the MTA, Amtrak, and NJ Transit filed a report stating Madison Square Garden was no longer compatible with Penn Station, saying, "MSG's existing configuration and property boundaries impose severe constraints." On September 14, 2023, the New York City Council voted 48–0 to renew the operating permit for Madison Square Garden for five years, the shortest-ever granted to the Garden by the city.
== Mode of action == Phrixotoxins 1 and 2 specifically block Kv4.2 and Kv4.3 channels by altering the voltage-dependent gating properties of these channels. Inhibition results from a shift of the conductance-voltage relation and steady-state inactivation properties to more depolarized potentials. These toxins also change Kv4.2 and Kv4.3 kinetics of activation and inactivation by a concentration-dependent increase of the time-to-peak current and time constant of current inactivation (Diochot 1999). Phrixotoxin-3 modulates voltage-gated sodium channels by causing a depolarizing shift in gating kinetics and by blocking the inward component of sodium current, thus preventing the channels from opening to a moderate depolarization, resulting in a reduced firing rate of the neurons (Bosmans 2006).
Peptides is a monthly peer-reviewed scientific journal covering the biochemistry, neurochemistry, pharmacology, and biological functions of peptides. It was established in 1980 and is published by Elsevier. The editor-in-chief is Karl-Heinz Herzig (University of Oulu).
=== Substrates === Norepinephrine Substrate-type norepinephrine releasing agents (e.g., ephedrine, amphetamine) Catecholaminergic activity enhancers (e.g., selegiline, PPAP, BPAP) Certain noradrenergic neurotoxins (e.g., DSP-4, xylamine)
Sources: en.wikipedia.org
CI mass spectrometry is a useful tool in structure elucidation of organic compounds. This is possible with CI, because formation of [M+1]+ eliminates a stable molecule, which can be used to guess the functional groups present. Besides that, CI facilitates the ability to detect the molecular ion peak, due to less extensive fragmentation. Chemical ionization can also be used to identify and quantify an analyte present in a sample, by coupling chromatographic separation techniques to CI such as gas chromatography (GC), high performance liquid chromatography (HPLC) and capillary electrophoresis (CE). This allows selective ionization of an analyte from a mixture of compounds, where accurate and precised results can be obtained.
This drastically revamped King Crimson had no plans to record in the studio, focusing instead on playing "reconfigured" versions of past material live. According to Levin, the band "were instructed/advised by Robert Fripp to look at the older classic King Crimson material as if we had written it. And so we did that with a lot of older material that the band had done before the '80s. We didn't actually cover that much of the '80s material outside of a few songs." For the most part, this approach would remain consistent for the remainder of the band's lifetime. In early 2014, the band's repertoire included songs from the run of albums between In the Court of the Crimson King and Larks' Tongues in Aspic for the first time since 1974, as well as reviving song material from Red. No songs with vocals by Belew were included in the setlist, although some instrumentals from his tenure were played. Some material from A Scarcity of Miracles was also incorporated into the band's repertoire. After rehearsing in England, King Crimson toured North America from 9 September to 6 October. Recordings from the Los Angeles dates were released as Live at the Orpheum; this included the newly-written instrumentals "Banshee Legs Bell Hassle" and "Walk On: Monk Morph Chamber Music". Tours of Europe, Canada, and Japan followed in the later half of 2015. Brand-new songs mainly written by Fripp and Jakszyk were debuted at the concerts, as well as drum showcases.
==== Media, social, internal and foreign affairs ==== Defense, National Security and Emergency Committee Diplomatic and Consular Affairs Committee Public Freedoms and Human Rights Committee Media Committee Social Affairs and Labor Committee Youth and Sports Committee Family and Women Committee Endowments, Religious Affairs and Fatwa Committee
== Inhibitors == Glycogen synthase kinase inhibitors are different chemotypes and have variable mechanisms of action; they may be cations, from natural sources, synthetic ATP and non-ATP competitive inhibitors and substrate-competitive inhibitors. GSK3 is a bi-lobar architecture with N-terminal and C-terminal, the N-terminal is responsible for ATP binding and C-terminal which is called as activation loop mediates the kinase activity, Tyrosine located at the C-terminal it essential for full GSK3 activity.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.